Article by Yippee-Ki-Yay

Swiss company Alcon AG: Everything you need to know before investing

Buy signal | Private publication | 25 Nov 2025

Alcon AG: The Empire of the Eye That Sees Far (And Your Wallet Too) 👁️💰

So, you want to know whether Alcon AG deserves a VIP spot in your super portfolio? Spoiler alert: this Swiss company, which plays in the big leagues of ophthalmology, has some serious arguments in its favour. Let me break it all down for you with the real figures under the bonnet.

Who is Alcon AG? The Jedi Master of Vision

Founded in 1945 and based in Geneva, Alcon is THE global leader in eye care. We're talking about a company that operates in more than 140 countries and helps millions of people see better every day. Their catalogue? Impressive: surgical equipment for cataracts, contact lenses, lasers for refractive surgery, solutions for glaucoma... In short, if it has to do with the eye, they do it, and they do it well.

With more than 25,000 employees and a massive global presence, Alcon combines cutting-edge innovation with financial stability. And the figures I have before me confirm that this machine is running at full speed.

2024 Performances: Houston, We've Taken Off! 🚀

The Income Statement: Green Everywhere (Or Almost)

In 2024, Alcon generated $9.911 billion in revenue, up 4.8% from $9.455 billion in 2023. It's not explosive growth, but in the medical field, consistency is king.

The net result? A magnificent $1.018 billion in 2024, compared to $974 million in 2023. That's an increase of +4.5%. Even better: in 2022, they were at only $335 million. In three years, they tripled their net profit. Respect.

The gross margin remains solid at 55.6% (5.515 billion), showing that they know how to convert their sales into juicy profits. Operating profit climbs to $1.414 billion (+37.8% vs 2023). Basically, the machine generates cash efficiently and consistently.

The Verdict: Solid as a Rock (Well, Almost)

Total assets at the end of 2024: $30.347 billion. That's a lot. Equity stands at $21.553 billion, giving a reasonable debt-to-equity ratio.

On the debt side, total debt (short- and long-term) stands at $5.136 billion, compared with $1.830 billion in cash and cash equivalents. Net debt is therefore around $3.3 billion, which is manageable for a company of this size. Financial leverage remains under control.

Cash Flow: The Star of the Show ⭐

Operating cash flow in 2024: $2.077 billion, a spectacular increase from $1.388 billion in 2023 (+49.6%). This is THE metric that makes me happy: Alcon generates real cash, not just accounting profit.

Capital expenditure (CapEx) is $670 million, leaving free cash flow of around 1.4 billion. With this windfall, they can comfortably finance their growth, repay debt and pay dividends (130 million in 2024).

The Complete Rating: We Break Everything Down 🔍

Right, let's get down to business. Here is my rating out of 5 for each important criterion, based on REAL financial data:

1. Turnover: 4/5 💪

Revenue in 2024: USD 9.911 billion (+4.8% vs 2023)

Growth is steady but not spectacular. Alcon is progressing steadily, driven by the ageing global population and the explosion of myopia among young people. The ophthalmology market is structurally buoyant, and Alcon is riding this wave perfectly.

History: 7.508 billion (2019) → 6.833 billion (2020, Covid) → 8.291 billion (2021) → 8.717 billion (2022) → 9.455 billion (2023) → 9.911 billion (2024). Average annual growth of ~7% over 5 years. Solid.

2. Net income: 4.5/5 📈

Net income for 2024: USD 1.018 billion (+4.5% vs. 2023)

This is where we reach the sublime. Net income has tripled since 2022 (335 million). Profitability is improving year after year, proof that management is optimising operations.

Diluted EPS for 2024 is USD 2.04, compared to 1.96 in 2023. And according to forecasts, it should continue to climb: USD 3.035 in 2025, USD 3.388 in 2026, up to USD 5.158 in 2029. This is the kind of trajectory that makes long-term investors salivate.

3. Debt: 3.5/5 ⚖️

  • Total debt: USD 5.136 billion
  • Cash: USD 1.830 billion
  • Net debt: ~USD 3.3 billion

The debt-to-equity ratio is around 23.8% (5.136 / 21.553), which remains reasonable. Long-term debt (4.538 billion) is largely covered by equity. And with operating cash flow of 2 billion per year, Alcon can easily service its debt.

On the plus side, forecasts show a gradual reduction in net debt (moving into negative territory by 2027, with -1.269 billion). In other words, they will accumulate more cash than they have debt. Nice!

4. Return on Equity (ROE): 3/5 📊

Okay, this isn't so impressive. An ROE of 7.2% is decent but not exceptional. To give you an idea, the best companies are running at 15-20%. But bear in mind that in the medical sector, with its heavy assets (equipment, R&D), it's not unusual to have a more modest ROE.

Forecasts show an improvement: 6.417% in 2025, then 7.098% in 2026, 7.805% in 2027... It's climbing slowly but surely. In 2029, it should reach 6.9%. Well, it's stagnating a bit. That's Alcon's weak point: return on equity could be better.

5. Market Performance: 3.5/5 📉

Let's be honest: 2024-2025 has been a bit of a struggle for the stock. The current price (CHF 61.58 ≈ USD 70-72) is down from its 2024 highs. But look at the forecasts in image 1:

  • Expected EPS for 2025: $3.035 (vs. $2.04 currently)
  • Expected EPS for 2026: $3.388
  • Forecast EPS for 2027: $3.903

Applying a conservative valuation multiple of 25x earnings (reasonable for the sector), the share could be worth $84-97 by 2026-2027, representing upside potential of 20-35%. Not bad for a defensive stock.
Book value per share is also expected to climb: $44.173 in 2025, $45.954 in 2026, $47.848 in 2027... The company is creating intrinsic value.

🎯 Overall average: 3.7/5

Verdict: A hidden gem in stealth mode

Alcon is not a hyped-up start-up that will multiply your capital tenfold in six months. It is a mature, world-leading company with solid fundamentals and an impressive ability to generate cash. The recent drop in its share price? A great entry point for patient investors.

Alcon's strengths:

  • Steady revenue growth (average annual increase of 5%)
  • Explosive growth in net income (tripled in three years)
  • Massive operating cash flow (over 2 billion per annum)
  • Dominant position in a buoyant market
  • Gradual debt reduction
  • Rising dividends (USD 0.346 in 2025, USD 0.58 in 2029)

Alcon's weaknesses:

  • ROE somewhat low (7-8%)
  • Recent stock market performance disappointing
  • Revenue growth not spectacular
  • Debt to monitor (even if it is falling)

2026-2027 Forecast: The Crystal Ball Time 🔮

Based on the data in your files, here's what lies ahead:

For 2026:

  • Expected revenue: USD 11.117 billion (+12% vs 2024)
  • Expected net income: USD 1.706 billion (+67% vs 2024!)
  • Expected EPS: USD 3.388
  • Estimated share price: USD 75-85 (based on P/E of 22-25x)

For 2027:

  • Expected revenue: USD 11.827 billion
  • Expected net income: USD 1.960 billion
  • Expected EPS: USD 3.903
  • Estimated share price: USD 85-98

Basically, if you buy at $70-72 today (equivalent to CHF 61.58), you can expect a 15-32% gain by 2027, not counting dividends. That's solid for a defensive stock.

Conclusion: Alcon, the Wise Choice (Not the Degenerate One) 🦉

Alcon AG is not your typical stock. It's not a cryptocurrency that will increase 100-fold in value, nor is it a tech start-up that's trending on Twitter. It's a century-old company, the undisputed global leader, helping millions of people see better every day.

Its fundamentals are rock solid: steady growth, rising profitability, massive cash flow, and gradual debt reduction. The 2026-2027 forecasts are frankly enticing, with a potential gain of 15-32% within 2-3 years.

The recent drop in the share price? A golden opportunity to buy at a discount. Growing dividends? A significant bonus. A dominant position in a growing market (ageing population, myopia)? A guarantee of long-term growth.

If your portfolio were a meal, Alcon wouldn't be the spectacular dessert, but rather the nourishing main course that fills you up and gives you energy for what's next. Solid, reliable, and with a little twist of innovation that makes all the difference.
So, are you ready to see the future more clearly (and more richly) with Alcon? 😎👁️💸

  • Signal : Buy
  • Budget/Investment : Medium
  • Reinforcement required : Yes, if under 52 CHF
  • Exposure : Low
  • Horizon : 1 to 2 years
  • Potential profitability : +15% to +32%
  • Ref. ISIN code : CH0432492467